Sera Prognostics, Inc. (NASDAQ:SERA) Insider Robert Gardner Harrison Sells 2,264 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Robert Gardner Harrison sold 2,264 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $6.47, for a total value of $14,648.08. Following the sale, the insider now directly owns 114,573 shares of the company’s stock, valued at approximately $741,287.31. The trade was a 1.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Robert Gardner Harrison also recently made the following trade(s):

• On Friday, January 10th, Robert Gardner Harrison sold 14,209 shares of Sera Prognostics stock. The shares were sold at an average price of $7.39, for a total transaction of $105,004.51.

Sera Prognostics Stock Up 0.6 %

Shares of NASDAQ:SERA opened at $6.37 on Wednesday. The firm has a market cap of $215.13 million, a price-to-earnings ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a 12 month low of $4.98 and a 12 month high of $12.35. The company’s fifty day simple moving average is $7.44 and its 200 day simple moving average is $7.31.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter last year, the company earned ($0.23) earnings per share. Research analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

Several institutional investors have recently bought and sold shares of the company. Barclays PLC grew its stake in shares of Sera Prognostics by 321.6% during the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock worth $308,000 after acquiring an additional 30,093 shares in the last quarter. Bank of New York Mellon Corp grew its position in Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after purchasing an additional 75,441 shares in the last quarter. Geode Capital Management LLC increased its stake in Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock valued at $4,578,000 after buying an additional 47,969 shares during the last quarter. Quest Partners LLC increased its stake in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after buying an additional 5,415 shares during the last quarter. Finally, State Street Corp lifted its position in Sera Prognostics by 8.8% during the 3rd quarter. State Street Corp now owns 425,093 shares of the company’s stock worth $3,316,000 after buying an additional 34,479 shares in the last quarter. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.